Eli Lilly, Zepbound

Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline access to the popular treatment.
What can't weight-loss meds do? Eli Lilly is going to test Zepbound as a treatment for addiction
Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster drug as a treatment for alcohol and drug addiction starting next year.
Zepbound tops Wegovy for weight loss in Eli Lilly study
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.
Lilly to offer single-dose vials of weight-loss drug on telehealth platform Ro
By Sneha S K (Reuters) -Telehealth company Ro said on Wednesday it will offer single-dose vials of Eli Lilly's weight-loss drug Zepbound to patients with obesity, becoming the first alternative platform for the lower-cost version of the drug to Lilly's own website.
Eli Lilly Will Sell Zepbound Through Telehealth Company Ro in a Swipe at Legal Copycats
Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the branded drugs, Lilly on Wednesday said it would sell a version of Zepbound through the telemedicine company Ro.
Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing
Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
The Zacks Analyst Blog Eli Lilly, Novo Nordisk's Amgen and Viking Therapeutics
Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
Wall Street Journal12d
Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger
While this adds competition to a market currently controlled by Eli Lilly LLY 0.13%increase; green up pointing triangle and Novo Nordisk, it also reinforces the dominance of the makers of ...
FiercePharma8d
Eli Lilly's Zepbound defeats Novo Nordisk's Wegovy in head-to-head weight loss trial
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...